DDInter923 DDInter576
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) treats {v} (Disease) alcohol dependence
alcohol dependence {u} (Disease) is treated by {v} (Compound) Disulfiram
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Betamethasone
Betamethasone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Disulfiram
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Oxycodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Disulfiram
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Betamethasone
Betamethasone {u} (Compound) downregulates {v} (Gene) FHL2
FHL2 {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) downregulates {v} (Gene) FOSL1
FOSL1 {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxycodone
Oxycodone {u} (Compound) causes {v} (Side Effect) Paraesthesia
Paraesthesia {u} (Side Effect) is caused by {v} (Compound) Disulfiram
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Methylprednisolone
Methylprednisolone {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Disulfiram
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Disulfiram
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Zidovudine
Zidovudine {u} (Compound) downregulates {v} (Gene) MRPS16
MRPS16 {u} (Gene) is downregulated by {v} (Compound) Disulfiram
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) treats alcohol dependence (Disease) and alcohol dependence (Disease) is treated by Disulfiram (Compound)
Infliximab may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Disulfiram (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Disulfiram (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Disulfiram (Compound)
Infliximab may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) downregulates FHL2 (Gene) and FHL2 (Gene) is upregulated by Disulfiram (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) downregulates FOSL1 (Gene) and FOSL1 (Gene) is upregulated by Disulfiram (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Disulfiram (Compound)
Infliximab may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Disulfiram (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Disulfiram (Compound)
Infliximab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is downregulated by Disulfiram (Compound)